Ironwood Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 2/6
Ironwood Pharmaceuticals has a total shareholder equity of $-321.7M and total debt of $623.6M, which brings its debt-to-equity ratio to -193.8%. Its total assets and total liabilities are $395.6M and $717.3M respectively. Ironwood Pharmaceuticals's EBIT is $119.3M making its interest coverage ratio 4.3. It has cash and short-term investments of $105.5M.
Informations clés
-193.8%
Ratio d'endettement
US$623.65m
Dette
| Ratio de couverture des intérêts | 4.3x |
| Argent liquide | US$105.52m |
| Fonds propres | -US$321.73m |
| Total du passif | US$717.35m |
| Total des actifs | US$395.62m |
Mises à jour récentes de la santé financière
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Recent updates
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Analyse de la situation financière
Passif à court terme: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: IRWD has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: IRWD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Couverture de la dette: IRWD's debt is well covered by operating cash flow (23.5%).
Couverture des intérêts: IRWD's interest payments on its debt are well covered by EBIT (4.3x coverage).